MedTrace Logo

Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

NCT00265291 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2008-10-10

No results posted yet for this study

Summary

Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.

Conditions

Interventions

DRUG

fluoxetine or desipramine

fluoxetine 5-40 mg/day desipramine 50-150 mg/day

Sponsors & Collaborators

  • National Institute of General Medical Sciences (NIGMS)

    lead NIH

Principal Investigators

  • Julio Licinio, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2006-05-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265291 on ClinicalTrials.gov